Collegium (COLL) news
Recent news
Collegium Pharmaceutical Q2 adjusted EPS USD 1.92 vs. IBES estimate USD 1.72
Collegium Pharmaceutical (COLL) reported second-quarter adjusted earnings per share (EPS) of USD 1.92, exceeding the IBES estimate of USD 1.72, according to recent financial results. The company also posted Q2 revenue of USD 188 million, surpassing the IBES revenue forecast of USD 180.9 million.…
AInvest Wire · Aug 6, 2026Collegium Pharmaceutical outlook FY revenue USD 825-855 million
AInvest Wire · Aug 6, 2026Coll sees FY adj. EBITDA $445M to $470M, saw $475M to $500M
AInvest Wire · Aug 6, 2026Collegium sees FY net revenue $825M to $855M, saw $865M to $895M
Collegium Pharmaceutical has updated its full-year net revenue guidance, projecting range of $825 million to $855 million , down from the previously expected $865 million to $895 million. This adjustment follows the company’s recent quarterly performance, which saw revenue of $193.5 million ,…
AInvest Wire · Aug 6, 2026Collegium Pharmaceutical reports inducement grants under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Jun 5, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.